

CURRICULUM VITAE

NAME AND ADDRESS

Lee J. Helman, M.D.
Scientific Director for Clinical Research,
Center for Cancer Research
National Cancer Institute,
National Institutes of Health
Building 31 Room 3A11
31 Center Drive MSC 2440
Bethesda MD 20892-2440

phone: 301 496 4257
fax: 301 480 4318
e-mail: helmanl@nih.gov

CITIZENSHIP

United States

MARITAL STATUS

Married, two children

EDUCATION

1976

BA with distinction
George Washington University
Washington, D.C.

1980

MD *Magna Cum Laude*
University of Maryland School of Medicine
Baltimore, Maryland

SPECIALTY BOARD CERTIFICATION

Internal Medicine 1983 certificate # 90797
Medical Oncology 1985 certificate # 90797

POSITIONS HELD

2008-2009 Acting Clinical Director, National Cancer Institute, National Institutes of Health,
Bethesda, MD

2007-present Scientific Director for Clinical Research, Center for Cancer Research, National
Cancer Institute, National Institutes of Health, Bethesda, MD

2005-2007 Acting Scientific Director for Clinical Research, Center for Cancer Research,
National Cancer Institute, National Institutes of Health, Bethesda, MD

2005-2007 Acting Chief, Medical Oncology, Center for Cancer Research, National Cancer
Institute, National Institutes of Health, Bethesda, MD

POSITIONS HELD *continued*

- 2001-present Deputy Director, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
- 1999-present Professor of Pediatrics, Part-Time, Johns Hopkins University, Baltimore Maryland
- 1999-present Professor of Oncology, Part-Time, Johns Hopkins University, Baltimore Maryland
- 1997-2007 Chief, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
- 1996-1997 Acting Chief, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
- 1995-1996 Acting Deputy Chief, Pediatric Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
- 1993-present Head, Molecular Oncology Section, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
- 1994-1998 Associate Professor of Pediatrics, Uniformed Services of the Health Sciences, F. Edward Hébert School of Medicine, Bethesda, MD
- 1990-1992 Medical Officer, Molecular Genetics Section, Pediatric Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
- 1987-1990 Senior Staff Fellow, Molecular Genetics Section, Pediatric Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
- 1986-1987 Biotechnology Fellow, Molecular Genetics Section, Pediatric Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
- 1984-1986 Medical Staff Fellow, Molecular Genetics Section, Pediatric Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
- 1983-1984 Medical Staff Fellow, Pediatric Branch and Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
- 1982-1983 Senior Assistant Resident in Internal Medicine, Barnes Hospital, St. Louis, MO
- 7/82-12/82 Chief Resident, Washington University Medical Service, St. Louis Veterans Administration Medical Center, St. Louis, MO
- 1981-1982 Junior Assistant Resident in Internal Medicine, Barnes Hospital, St. Louis, MO
- 1980-1981 Internship in Internal Medicine, Barnes Hospital, St. Louis, MO

STATE LICENSURE Maryland (#D25357, 1980) exp. 09/30/10

SOCIETIES

American Association of Cancer Research, Member

- Clinical Pharmacology/Modality-based Clinical Research Section, Clinical Research Subcommittee, 2001 Program Committee, 2001
- Pediatric Cancers-Basic Science to the Clinic Section of the Clinical Research Subcommittee, 2003 Program Committee
- Pediatric Oncology Task Force, 2003-present, Chair, 2009-present
- Subsection Committee Member, 2004 Program Committee
- Pediatric Cancer-Basic Science Section, Cellular, Molecular and Tumor Biology Subcommittee; Pediatric Cancer-Clinical Investigations Section, Clinical Research Subcommittee, 2004 Program Committee
- Grants Committee, 2004-2006
- Pediatric Cancers-Basic Science and Pediatric Cancer-Clinical Investigations Sections, 2005 Program Committee
- AACR-NCI-EORTC International Conferences Scientific Advisory Committee, 2006-present
- Sarcoma Expert Panel, 2007
- Translational Cancer Medicine Think Tank, 2007
- Centennial Award for Childhood Cancer Research Selection Committee 2007
- Special Conferences Committee 2007-2010
- Program Committee Co-Chairperson, 2008 Annual Meeting, New Concepts in Organ-Site Research Pediatric Cancers, Diagnosis and Treatment of Pediatric Cancer: From 20th Century successes to 21st Century Opportunities
- Science Education Committee 2008-2011
- 2008 Annual Meeting, Meet-the-Expert session: Translating Cancer Biology into Cancer Medicine: IGF1R Ab Development in Sarcomas
- Clinical and Translational Research Committee 2009-2012
- 2010 Annual Meeting, Pediatric Cancer Educational session: New Perspectives in Pediatric Cancer - From Preclinical Models to Targeted Therapies: Targeting the IGF1R in Pediatric Sarcomas – An Evolving Story
- 2010 Annual Meeting, New Concepts in Organ Site Research session: Bridging the Gap: Moving Laboratory Discoveries into Clinical Trials: Development of “Achilles Heel” Screening in Rhabdomyosarcoma Identifies Novel Therapeutic Targets

American Society of Clinical Oncology, Member

- Program Committee 1990
- Board of Directors (Specialty Other Than Medical Oncology/Hematology), 2003-2006
- Audit Committee, 2003-2006, Chair 2004-2006
- 2004, 2005 International Travel Grants Mentorship Program
- Cancer Communications Committee 2004-2006
- Board Liaison to Committee and Task Forces 2004-2006
- Governance Task Force 2005
- Bylaws Committee Chair-Elect 2007-2008, Chair 2008-2009, Immediate Past Chair 2009-2010
- Special Awards Selection Committee 2007
- Advanced Clinical Research Award in Sarcoma Subcommittee, ASCO Cancer Foundation 2008
- Chair, Clinical Science Symposium, Emerging Targets for Sarcoma Therapy, 2008 Annual Meeting

SOCIETIES continued

— Chair Education Session: Translocation-Specific Sarcomas: Can Molecular Targets Translate to Therapeutics?: IGF1R Targeting of Translocation-Associated Sarcomas, 2010 Annual Meeting

Connective Tissue Oncology Society

— Founding Member 1995

— Board of Directors 1996-1998

— Treasurer 1998-1999; Secretary 1999-2000; Vice President 2000-2001, President 2001-2002, Immediate Past President 2002-2003

NATIONAL SERVICE

Cancer Research Foundation of America Grant Reviewer, 1990

Israel Science Foundation Grant Reviewer, 1993

Dutch Cancer Society Grant Reviewer, 1994

American Cancer Society Grant Reviewer

International Human Frontier Science Program Grant Reviewer, 1995

U.S. Army Medical Research and Materiel Command Breast Cancer Research Program-
Endocrinology 3 Study Section, 1996

National Cancer Institute of Canada — Program Project Review, 1996

Children's Cancer Foundation — Medical Advisory Board, 1996-2008; Chairman, 2000-2008; Grant
Review Panel Chairman, 2000-2008

Children's Inn at NIH — Board of Directors & Clinical Advisor, 1997-present; Secretary, Board of
Directors, 2004-2005, Co-Chair, Board Development Committee, 2005-present

Dept. of Veterans Affairs, VA Palo Alto Health Care System Grant Reviewer, 1997

Israel Cancer Research Fund - Scientific Review Panel, 1997-1999, 2008

Association for International Cancer Research Grant Reviewer, 1998

US Israel Bi-National Science Foundation Grant Reviewer, 1998

Ohio Cancer Research Associates Grant Reviewer, 1999

Israel Cancer Research Fund Scientific Advisory Board, 1999-present

Candlelighters Ad Hoc Grant Reviewer, 1999, 2000

Children's Oncology Group Ewing's Biology Committee, 2000-present, Bone Sarcoma Disease
Committee, 2001-present, Scientific Advisory Committee, 2001-present

American Joint Committee on Cancer Bone Task Force, 2000-present

Canadian Institutes of Health Research Grant Reviewer, 2000

Scientific Review Board, Cancer Research Foundation of America's Hope Street Kids, 2000-present

International Consortium for CURE of Childhood Cancer in China, National Cancer Institute
Representative and Senior Consultant, 2000-present

Scientific Advisory Board, Children's Cancer Research Institute, Vienna, Austria, 2001-present

Johns Hopkins Oncology Center, Advisory Committee for the Lab Research Training in Pediatric
Oncology-Hematology Training Grant, 2001-present

Cancer Research UK, United Kingdom Grant Reviewer, 2001-present

Sarcoma Foundation of America Medical Advisory Board, 2002-present

National Cancer Institute of Canada Review Team for Program Project Applications, 2002

Ireland-Northern Ireland-National Cancer Institute Cancer Consortium, Implementation Group
Member, 2003-present; Strategic Advisory Group Member, 2006-present, Member
Scholar Exchange Working Group, 2008-present

NATIONAL SERVICE continued

European Commission's 6th Framework Programme for Research and Demonstration Activities,
Major Diseases Unit for Cancer-Evaluation of European Projects on Cancer
Research, 2005

Coaches Curing Kids' Cancer, Co-Chair Medical Advisory Board, 2005 to present

MD Anderson Cancer Center, External Advisory Board for the Department of Sarcoma Medical
Oncology, 2006

Samuelsson Foundation Grant Reviewer, 2006-present

Cincinnati Children's Hospital Medical Center Research Foundation, Scientific Advisory Council,
2006

Life Raft Group Grant Reviewer, 2006-present

Maine Institute for Human Genetics & Health, Founding Member, 2007, and Chair, Scientific
Advisory Board, 2007-2009

Children's Research Institute at Children's National Medical Center, Scientific Advisory Committee,
2007-2010

Alex's Lemonade Stand Fund Grant Program Grant Reviewer, 2008-present

Foster Foundation Advisory Board, 2008-present

EuroBoNeT Consortium, External Advisory Board, 2009-2011

8th International Symposium on Targeted Anticancer Therapies (TAT 2010), Organizing Committee,
2009-2010

Irish Cancer Society, Grant Reviewer, 2010

Irish Medicines Board, Expert Panel of the Clinical Trials Subcommittee, 2010

Clinical Trials Network of Texas, CTNet, External Advisory Board, 2010-2013

Baylor College of Medicine, External Advisory Board, Project: Targeted Therapies for Metastatic
Osteosarcoma, 2010-2015

NIH SERVICE

Ad Hoc Review Committee — Programs of Excellence in Endocrinology, National Institute of
Diabetes and Digestive and Kidney Diseases, 1990

Ad Hoc Review Committee — Endocrine Aspects of Human Neoplasia, National Institute of
Diabetes and Digestive and Kidney Diseases, 1990

Institutional Review Board Panel, 1995-1997

Non-Melanoma Vaccine Working Group Steering Committee, NCI 1998-present

NCI/Frederick Cancer Research and Development Center Committee, 1998-present

NCI Intramural Advisory Board, NIH, 1998-2002; Vice Chairman, 2000, Chairman, 2001, 2002;
NCI Intramural Working Group Co-Chair, 2000, 2001

Pediatric Care Committee, Clinical Center, NIH, 1998-2000

Office of Research Services Advisory Committee, NIH, 1998-2002

White Ribbon NCI Ethics Panel, 1999-present

Physician Data Query, NCI, Reviewer of Clinical Trial Protocols, 1999-present

NIH Clinical Research Training Program Tutor/Mentor, 2000-2008

NIH Clinical Center Review Team Bench-to-Bedside Awards, 2001, 2002, 2003, 2004, 2005

NCI Cellular, Molecular and Developmental Biology Faculty Steering Committee, 2001-2005

NCI Metastasis Working Group Steering Committee 2003-present

NCI Title 42 Standing Committee, 2002-2008

NCI Intramural Clinical Trials Committee, 2002-present

NCI Sarcoma Progress Review Group, Executive Director, 2003-present

NIH SERVICE continued

Board of Governors, Warren Grant Magnuson Clinical Center, NIH, 2003-2008 (Restructured and Renamed Advisory Board for Clinical Research in 2004)
Member, Clinical Center Careers in Clinical Research Committee, Advisory Board for Clinical Research, NIH, 2003-present, Chair, 2003-2006
NCI Roundtable Meeting of the Translational Research Working Group, 2006
NCI Clinical Trials Operations Committee, 2006-2008; renamed Clinical and Translational Research Operations Committee, 2008-present
NCI Molecular Targets Faculty Steering Committee, 2006-present
NCI Clinical Trials Advisory Committee, *Ex Officio*, 2007-present
NIH PET Steering Committee, Chair, 2007-2009
NCI Center of Excellence-Molecular Oncology Steering Committee, 2007
U.S.-Japan Cooperative Cancer Research Program Steering Committee, 2007-present
NIH Research Festival Symposia Co-Chair, 2008
Investigational Drug Steering Committee PAM (PI3K/Akt/mTOR) Task Force, 2008
NIH Intramural Working Group 2009-2011
NCI Center for Cancer Research Grand Rounds, *Recent Advances in Ewing's Sarcoma*, May 2008
NIH Bone Marrow Stromal Cell Transplantation Oversight Committee, 2008-present
NCI Experimental Therapeutics (NExT) Development Committee, Co-chair, 2009-present; Senior Advisory Committee, 2009-present

EDITORIAL BOARDS

Editorial Board, *Journal of Clinical Oncology*, 2008-2010
Associate Editor, *Clinical Cancer Research* 2002-2007; Senior Editor 2007-2010
Associate Editor, *Cancer Research*, 2000-2007
Consulting Editor, *SARCOMA - A multidisciplinary Journal* (through 2005)
Editorial Board, *Clinical Proteomics*, 2003-2004
Associate Editor, *Journal of Pediatric Hematology/Oncology*, 2003-2004
Associate Editor, Principles and Practice of Pediatric Oncology, 6th Edition, July 2009-May 2011

HONORS AND AWARDS

Phi Beta Kappa, George Washington University, Washington, D.C. 1976
Alpha Omega Alpha, University of Maryland School of Medicine, Baltimore, MD 1979
ASCO Travel Awards 1986 and 1987
American Society of Clinical Investigation 1996
Israel Cancer Research Fund's Elliott Osserman Award for Distinguished Service in Support of Cancer Research 1999
NIH Merit Award 2002
Association of American Physicians 2003
NCI Director's Award 2005
NIH Director's Award 2006, 2009
Federal Technology Transfer Award 2005, 2006
The Life Raft Group Humanitarian Award 2008

PATENTS

Novel Immunotherapeutic Methods and Vaccines, 1999 U.S. Patent No. 5,997,869.

Berzofsky J, Helman L, Mackall C, Van Den Broeke L, inventor; DHHS, assignee.
Immunogenic Peptides And Methods Of Use For Treating And Preventing Cancer.
Patent Pending, Filed in 2005. Application No. 12/092,449. Pending [Patent]

RESEARCH INTERESTS

Research focuses on three major themes related to the biology and treatment of pediatric sarcomas: (1) the role of insulin-like growth factors on the biology of these tumors; (2) identification of the molecular mechanisms of metastases using animal models of spontaneously metastatic tumors; (3) translation of these findings into treatments to improve the outcome of patients with pediatric sarcomas.

INVITED LECTURES

International Symposium on Childhood Rhabdomyosarcoma-Speaker, Children's Hospital, Columbus, OH, October 1989

1st Robert Steel Foundation International Symposium on Molecular Genetics and Developmental Biology of Embryonal Rhabdomyosarcoma and Sarcomas of Bone in Children-Speaker, Memorial Sloan-Kettering Cancer Center, New York, NY, June 1990

UCLA Symposium on The Biology of Sarcomas-Speaker, Lake Tahoe, CA, March 1990

American Association of Cancer Research-Session Chairs, Biology of Cancer Poster Discussion, 1992, and Molecular Markers, Orlando, FL, 1993

Interdisciplinary Sarcoma Symposia-Speaker, Boca Raton, FL, February 1993

4th International Symposium on Insulins, IGFs, and Their Receptors-Speaker, Woods Hole, MA, April 1993

9th Annual Forbeck Forum-Speaker, Hilton Head, SC, October 1993

1995 Endocrine Society Annual Meeting Plenary Session-Speaker, Washington, DC, May 1995

National Cancer Institute Clinical Oncology Grand Rounds-Guest Speaker, National Institutes of Health, Bethesda, MD, 1995 and 1997

Second Annual Connective Tissue Oncology Society Meeting-Speaker, Toronto, Canada, October 1996

Second Osteosarcoma Research Conference-Speaker, Bologna, Italy, November 1996

Clinical Center Grand Rounds, National Institutes of Health-Guest Speaker, Bethesda, MD, 1996 and 1998

American Society of Clinical Oncology-*Meet the Professor*, Denver, CO, May 1997

Memorial Sloan-Kettering Cancer Center Division of Solid Tumor Oncology Conference-Speaker, New York, NY, May 1997

Robert Steel Foundation International Symposium on Sarcomas, Memorial Sloan-Kettering Cancer Center-Speaker, New York, NY, September 1997

INVITED LECTURES *continued*

Wells Center for Pediatric Research Combined Seminar Series-Speaker, Indiana University, Indianapolis, IN, October 1997

8th International Congress on Anti-Cancer Treatment-Speaker Paris, France, Feb 1998

Centernet Grand Rounds Program, Clinical Center, National Institutes of Health-Guest Speaker, Bethesda, MD, March 1998

American & European Musculoskeletal Tumor Societies Presidential-Guest Lecturer, Washington, D.C., May 1998

Frances Hester Dornette Lecture, 16th Annual, The Jewish Hospital-Guest Lecturer, Cincinnati, OH, May 1998

Robert Steel Foundation International Symposium on New Strategies for Stimulating and Augmenting Host Resistance to Malignant Cells-Speaker, Memorial Sloan-Kettering Cancer Center, New York, NY, October 1998

Hematology/Oncology Research Seminar, Children's Hospital of Philadelphia-Speaker, Philadelphia, PA, February 1999

Johns Hopkins University School of Medicine, Department of Oncology-Visiting Professor, Baltimore, MD, February 1999

Pharmacology and Toxicology Seminar Series, Dartmouth Medical School-Speaker, Hanover, NH, March 1999

American Society of Clinical Oncology 35th Annual Meeting-Panel Discussant Pediatric Solid Tumors, Atlanta, GA, May 1999

International Meeting on Multidisciplinary Approach to Treatment of Bone and Soft-Tissue Sarcomas-Speaker, Naples, Italy, June 1999

Serono Symposia USA's International Symposium on Growth Hormone in Immune Reconstitution: Basic and Clinical Studies-Speaker, St. Petersburg Beach, FL, October 1999

American Association for Cancer Research 91st Annual Meeting, Symposia Exploiting the Genetic Defects of Pediatric Tumors-Speaker, San Francisco, CA, April 2000

European Musculoskeletal Oncology Society-Mario Campanacci Lecturer, London, England, May 2000

American Society of Clinical Oncology 36th Annual Meeting, Distinguishing Between Fact and Fiction in the Treatment and Pathogenesis of Pediatric Solid Tumors-Education Session Chair New Orleans, LA, May 2000

Childhood Bone Sarcomas-Molecular Characterization and Growth Factors- Distinguished Guest Speaker Symposium, Hadassah Hospital, Jerusalem, Israel, July 2000

Training Scientists for the Forthcoming Decade, The Hospital for Sick Children-Keynote Speaker, Toronto, Canada, January 2001

Musculoskeletal Tumor Society Specialty Day, Diagnosis and Staging Session, Adjuvant Therapy: Immunotherapy-Speaker, San Francisco, CA, March 2001

European Organization for Research and Treatment of Cancer, Soft Tissue and Bone Sarcoma Group 25th Anniversary Meeting on Sarcomas-Speaker, Aarhus, Denmark, April 2001

INVITED LECTURES continued

University of Minnesota Department of Orthopaedic Surgery, Medical School and University of Minnesota Cancer Center-Visiting Professor in Musculoskeletal Oncology, April 2002

American Association for Cancer Research 93rd Annual Meeting-Forum Participant, The Best Targets in Sarcoma, San Francisco, April 2002

The 10th Federation Meeting of Korean Basic Medical Scientists 2002, Korean Society of Pathologists-Pathobiology of Pediatric Tumors-Guest Speaker, Seoul, Korea, May 2002

American Society of Clinical Oncology 38th Annual Meeting, Co-Chair-Discussant, Scientific Session, Sarcoma, Orlando, FL, May 2002

Symposium on Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis 1 and on Microarrays in Neurofibromatosis 1, The National Neurofibromatosis Foundation Meeting-Invited Participant, Aspen, CO, June 2002

Seattle Cancer Care Alliance/Sarcoma Service, University of Washington School of Medicine-Visiting Professor, Seattle, WA, June 2002

Cancer in Children, Adolescents and Young Adults Conference, Southern Illinois University School of Medicine-Keynote Speaker, Springfield, IL, September 2002

2nd Pediatric Oncology Conference-Methods In Drug Development, European School of Oncology-Invited Faculty, Rome, Italy, March 2003

National Cancer Institute Center for Cancer Research Grand Rounds, National Institutes of Health-Guest Speaker, Bethesda, MD, June 2003

VI International Colloquium on Hematology & Oncology-Invited Speaker, Ixtapa, Mexico, August 2003

Experimental Hematology-Hematology/Oncology Seminar Series, Children's Hospital Medical Center-Guest Speaker, Cincinnati, OH, September 2003

Grand Rounds, St. Jude Children's Research Hospital-Guest Speaker, Memphis, TN, September 2003

Symposium Advances and Prospects in Pediatric Cancer Research, Children's Cancer Research Institute, St. Anna Children's Hospital-Speaker, Vienna, Austria, November 2003

Baylor College of Medicine-Guest Speaker, Houston, TX, December 2003

Huntsman Cancer Institute, Sarcoma Symposium-Invited Speaker, February 2004

The University of Texas MD Anderson Cancer Center and Memorial Sloan-Kettering Cancer Center, Adolescent and Young Adult Symposium, *Sarcomas in Adolescents and Young Adults*-Invited Speaker, April 2004

Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH, Grand Rounds speaker-September 2004

Children's Hospital, Boston, Orthopedic Research Seminar Series-Invited Speaker, December 2004

Grand Rounds, Cancer Institute of New Jersey-Grand Rounds-Invited Speaker, New Brunswick, NJ, February 2005

INVITED LECTURES continued

Tulane/Louisiana State University Center for Gene Therapy, Joint Journal Club-Invited Speaker, New Orleans, LA, March 2005

Sarcoma Meeting Stuttgart-Key Speaker, Stuttgart, Germany, June 2005

International Society of Pediatric Oncology 37th Conference-Keynote Lecture on behalf of the American Society of Clinical Oncology, Vancouver, BC, Canada, September 2005

Robert Steel Foundation for Pediatric Cancer Research, International Symposium, *Molecular Signatures Distinguishing the Clinical Behavior of Human Malignancies and Sensitivity to Targeted Therapeutics*-Invited Speaker, New York, NY, November 2005

University of Chicago-Suzanne Berman Visiting Professor, Chicago, IL, December 2005

American Association for Cancer Research, *Meet-the-Expert Sunrise Session*-Invited Speaker, Annual Meeting 2006, Washington, DC, April 2006

American Society of Clinical Oncology, Education Session, *What Do You Do When Adult Cancers Occur in Children?*-Invited Speaker, Annual Meeting 2006, Atlanta, GA, May 2006

Interdisciplinary Meeting on Soft-Tissue Sarcomas-Invited Speaker, Milan, Italy, May 2006

Connective Tissue Oncology Society 12th Annual Meeting-Nina Axelrad Lecture, Venice, Italy, November 2006

Texas Children's Cancer Center's Donald J. Fernbach, M.D. Lectureship: Series Research Seminar-Invited Speaker, Houston, TX, November 2006

3rd All-Ireland Cancer Conference-Plenary Speaker, Belfast, Northern Ireland, November 2006

Gordon Research Conference, *Insulin-like Growth Factors in Physiology & Disease*-Invited Speaker, Ventura, California, March 2007

American Association for Cancer Research 98th Annual Meeting-Moderate Forum, Use of Anti-Angiogenesis Therapy in Pediatric Cancer, *New Approaches to Anti-Angiogenic Therapy in Pediatric Cancer: From Pets to People*, Los Angeles, CA, April 2007

American Association for Cancer Research 98th Annual Meeting-Co-Chair Session: New Concepts in Organ-Site Research & Speaker: *The IGF/mTOR Pathway in Round Cell Sarcomas-Therapeutic Implications*, Los Angeles, CA, April 2007

Croatian Medical Association and Croatian Oncological Society, Workshop: Clinical Oncology in Croatia-Strategic Planning and Beyond, *Overview of Pediatric Oncology*, Zagreb, Croatia, May 2007

American Society of Clinical Oncology Annual Meeting, CDA/YIA Scientific Session, Expert Panel/Discussant, June 2007

Croatian Medical Association and Croatian Oncological Society, 1st U.S.-Croatian Conference on the ICT, Biotechnology and Pharmaceutical Industry, Special lecture: *The Scientific Collaboration between U.S. and Croatia in Oncology: The Role of the U.S. National Cancer Institute*, Split, Croatia, October 2007

Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Visiting Professorship Seminar, *From IGF to mTOR Signaling in Pediatric Sarcomas-Opportunities for Novel Therapeutic Intervention*, Washington, DC, January 2008

INVITED LECTURES continued

Pediatric & Adolescent Osteosarcoma...Progress from the Past, Prospects for the Future, Keynote Summary Speaker, *Strategies to Explore New Approaches in the Investigation and Treatment of Osteosarcoma*, Children's Cancer Hospital at The University of Texas, M.D. Anderson Cancer Center, Houston, TX, March 2008

American Association for Cancer Research, Advances in Cancer Research: From the Laboratory to the Clinic, Novel Therapeutics, Invited Speaker: *From IGF1R to mTOR and Back Again-Targeting the IGF Signaling Pathway in Sarcomas*, Dead Sea, Jordan, March 2008

European Society for Medical Oncology (ESMO) International Symposium on Soft-Tissue Sarcomas and GIST, Invited Faculty and Speaker, Educational Program and Faculty Roundtable Discussion, Milan, Italy, May 2008

European Commission 3rd Workshop on Molecular Targets for Cancer, Invited Speaker, *Targeting the IGF1R in Pediatric and Adult Sarcomas*, Bergen, Norway, July 2008

American Academy of Orthopaedic Surgeons/Orthopaedic Research Society's Molecular Biology and Therapeutics in Musculoskeletal Oncology Research Symposium, Translating Ewing's Biology to Clinical Trials, Salt Lake City, UT, September 2008

American Academy of Pediatrics, Section on Surgery Meeting, Symposium: Innovative New Technologies to Fight Pediatric Cancer: AAP Session on Cancer, Invited Faculty, *Targeted Therapy for Pediatric Sarcomas*, Boston, MA, October 2008

20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Scientific Committee and Chair, Plenary Session on Proffered Papers, Geneva, Switzerland, October 2008

Children's Cancer Research Institute, 20th Anniversary Celebration International Scientific Symposium - Innovation and Translation-Bridging the Gap in Pediatric Oncology, Co-Chair Therapeutic Promise of Receptor Tyrosine Kinases Session & Keynote Speaker, *Targeting the IGF Pathway in Pediatric Sarcomas: Lessons Learned and Questions Raised*, Vienna, Austria, November 2008

4th All-Ireland Cancer Conference, Invited Speaker: Session "Cancer in Children, Adolescents and Young Adults," chair session Clinical Trials-From Drug Discovery to Bedside, and mini-symposium presented by the Irish Association for Cancer Research, Translating Cancer Biology into Cancer Medicine, Dublin, Ireland, November 2008

University of Maryland, Cancer Dynamics Colloquium, Invited Speaker: *Translating Cancer Biology into Cancer Medicine*, College Park, MD, December 2008

National Cancer Institute, Immunology & Inflammation Seminar Series, Invited Speaker: *Targeting the IGF Pathway in Pediatric Sarcomas-Lessons Learned and Questions Raised*, Frederick, MD, February 2009

Andrew H. Weinberg Memorial Lecture, 2009 Invited Speaker: *Targeting IGF Signal in Sarcomas: Past-Present and Future*, Dana-Farber Cancer Institute, Boston, MA, April 2009

Weinberg Memorial Lecture, Pediatric Grand Rounds, Invited Speaker: *Identifying Pathways Critical for Survival of Pediatric Sarcomas: Something Old, Something New*, University of Chicago, Chicago, IL, September 2009

Vanderbilt-Ingram Cancer Center, Ingram Distinguished Lecturer: *Achilles Heel: Screening in Rhabdomyosarcoma Identifies Novel Therapeutic Targets*, Nashville, TN, February 2010

INVITED LECTURES continued

European Society for Medical Oncology (ESMO), Invited Lecturer: Session - How to Use Molecular Targeted Therapy, *Advances in Inhibition of IGFR*, Milan, Italy, March 2010

Huntsman Cancer Institute Seminar Series, Invited Speaker: *Translating Cancer Biology into Cancer Medicine: IGFR Ab Development-Lessons Learned and New Questions*, University of Utah, Salt Lake City, UT, April 2010

BIBLIOGRAPHY

1. Von Hoff DD, Penta JS, Helman LJ, and Slavik M. Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration. *Cancer Treat Rep*, 61(4):745-8, 1977.
2. Von Hoff DD, Rozenzweig M, Soper WT, Helman LJ, Penta JS, Davis HL, and Muggia FM. Whatever happened to NSC ____? An analysis of clinical results of discontinued anticancer agents. *Cancer Treat Rep*, 61(5):759-68, 1977.
3. Plaut SM, Walker-Bartnick L, Helman LJ, Ginsberg R, Rapoport RG, Plaut JM, Cannon MJ, and Dies RR. Improving staff-student relations: effects of a humanistic medicine programme. *Medical Teacher*, 2(1):32-9, 1980.
4. Helman LJ, Ozols RF, and Longo DL. Thrombocytopenia and extragonadal germ-cell neoplasm. (Letter) *Ann Int Med*, 101(2):280, 1984.
5. Helman LJ, Thiele CJ, Linehan WM, Nelkin BD, Baylin SB, and Israel MA. Molecular markers of neuroendocrine development and evidence of environmental regulation. *Proc Natl. Acad Sci USA*, 84:2336-9, 1987.
6. Helman LJ, Gazdar AF, Park J-G, Cohen PS, Cotelinghan JD, and Israel MA. Chromogranin A expression in normal and malignant human tissues. *J Clin Invest*, 82:686-90, 1988.
7. Helman LJ, Ahn TG, Levine MA, Allison A, Cohen PS, Cooper MJ, Cohn DV, and Israel MA. Molecular cloning and primary structure of human chromogranin A (secretory protein I) cDNA. *J Biol Chem*, 263(23):11559-63, 1988.
8. Gazdar AF, Helman LJ, Israel MA, Russell EK, Linnoila RI, Mulshine JL, Schuller HM, and Park J-G. Expression of neuroendocrine cell markers L-Dopa decarboxylase, chromogranin A, and dense core granules in human tumors of endocrine and nonendocrine origin. *Cancer Res*, 48:4078-82, 1988.
9. Cooper MJ, Helman LJ, Evans AE, Swamy S, O'Connor DT, Helson L, and Israel MA. Chromogranin A expression in childhood peripheral neuroectodermal tumors. *Adv Neuroblastoma*, 2:175-84, 1988.
10. Reeves SA, Helman LJ, Allison A, and Israel MA. Molecular cloning and primary structure of human glial fibrillary acidic protein. *Proc Natl Acad Sci USA*, 86:5178-82, 1989.
11. El-Badry OM, Romanus JA, Helman LJ, Cooper MJ, Rechler MM, and Israel MA. Autonomous growth of a human neuroblastoma cell line is mediated by insulin-like growth factor II. *J Clin Invest*, 84:829-39, 1989.

12. Helman LJ, Cohen PS, Averbuch SD, Cooper MJ, Keiser HR, and Israel MA. Neuropeptide Y expression distinguishes malignant from benign pheochromocytoma. *J Clin Oncol*, 7:1720-5, 1989.
13. Peng Z, Calvert I, Clark J, Helman LJ, Kahn R, and Kung HF. Molecular cloning, sequence analysis and mRNA expression of human ADP-ribosylation factor. *Biofactors*, 2(1):45-9, 1989.
14. Cooper MJ, Helman LJ and Israel MA. Molecular biology and the pathogenesis of neuroblastoma and pheochromocytoma. *Cancer Cells*, 7:95-9, 1989.
15. Levine MA, Smallwood PM, Moen, Jr. PT, Helman LJ and Ahn TG. Molecular cloning of $\beta 3$ subunit, a third form of the Gprotein β - subunit polypeptide. *Proc Natl Acad Sci USA*, 87:2329-33, 1990.
16. Helman LJ, Sack N, Plon SE and Israel MA. The sequence of an adrenal specific human cDNA, pG2. *Nuc Acid Res*, 18(3):685, 1990.
17. Cooper MJ, Hutchins GM, Cohen PS, Helman LJ, Mennie RJ and Israel MA. Human neuroblastoma tumor cell lines correspond to the arrested differentiation of chromaffin adrenal medullary neuroblasts. *Cell Growth*, 1:149-59, 1990.
18. El-Badry OM, Minniti CP, Kohn EL, Houghton PJ, Daughaday WH and Helman LJ. Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. *Cell Growth Differ*, 1:325-31, 1990.
19. Cohen PS, Cooper MJ, Helman LJ, Thiele CJ, Seeger RC and Israel MA. Neuropeptide Y expression in the developing adrenal gland and in childhood neuroblastoma tumors. *Cancer Res*, 50:6055-61, 1990.
20. Levine MA, Dempsey MA, Helman LJ and Ahn TG. Expression of chromogranin-A messenger ribonucleic acid in parathyroid tissue from patients with primary hyperparathyroidism. *J Clin Endocrinol Metab*, 70(6):1668-73, 1990.
21. Prior TI, Helman LJ, FitzGerald DJ and Pastan I. Cytotoxic activity of a recombinant fusion protein between insulin-like growth factor I and *pseudomonas* exotoxin. *Cancer Res*, 51:174-80, 1991.
22. El-Badry OM, Helman LJ, Chatten J, Steinberg SM, Evans AE and Israel MA. Insulin like growth factor II-mediated proliferation of human neuroblastoma. *J Clin Invest*, 87:648-57, 1991.
23. Crouch GD and Helman LJ. All-*trans*-retinoic acid inhibits the growth of human rhabdomyosarcoma cell lines. *Cancer Res*, 51:4882-7, 1991.
24. Minniti CP, Maggi M and Helman LJ. Suramin inhibition of human rhabdomyosarcoma cell growth may occur through a block of the IGF-I receptor. *Cancer Res*, 52:1830-5, 1992.

25. Felix CA, Kappel CC, Mitsudomi T, Nau MM, Tsokos M, Crouch GD, Nisen PD, Winick NJ and Helman LJ. Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. *Cancer Res*, 52:2243-7, 1992.
26. Minniti CP, Kohn EC, Grubb JH, Sly WS, Oh Y, Rosenfeld RG and Helman LJ. The IGF-II/Mannose 6-phosphate receptor mediates insulin like growth factor-II induced motility in human rhabdomyosarcoma cells. *J Biol Chem*, 267:9000-4, 1992.
27. Park J-G, Choe GY, Helman LJ, Gazdar AF, Yang H-K, Kim J-P, Park SH, and Kim YI. Chromogranin-A expression in gastric and colon cancer tissues. *Int J Cancer*, 51:189-94, 1992.
28. Crouch GD, Kalebic T, Tsokos M and Helman LJ. Ara-C treatment leads to differentiation and reverses the transformed phenotype in a human rhabdomyosarcoma cell line. *Exp Cell Res*, 204:210-6, 1993.
29. Parmer RJ, Xiao-Ping X, Hong-Jiang W, Helman LJ and Petz LN. Secretory protein traffic: chromogranin A contains a dominant targeting signal for the regulated pathway. *J Clin Invest*, 92(2):1042-54, 1993.
30. Minniti CP, Tsokos M, Newton, Jr. WA and Helman LJ. Specific expression of insulin-like growth factor-II in rhabdomyosarcoma tumor cells. *Am J Clin Path*, 101(2):198-203, 1994.
31. Hirschfeld S and Helman LJ. Diverse roles of insulin-like growth factors in pediatric solid tumors. *In Vivo*, 8:81-90, 1994.
32. Luján HD, Mowatt MR, Helman LJ and Nash TE. Insulin-like growth factors stimulate growth and L-cysteine uptake by the intestinal parasite *Giardia lamblia*. *J Biol Chem*, 269(18):13069-72, 1994.
33. Zhan S, Shapiro DN and Helman LJ. Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma. *J Clin Invest*, 94(1):445-8, 1994.
34. Kappel CC, Velez-Yanguas MC, Hirschfeld S and Helman LJ. Human osteosarcoma cell lines are dependent on insulin-like growth factor I for *in vitro* growth. *Cancer Res*, 54(10):2803-7, 1994.
35. Wexler LH and Helman LJ. Pediatric soft-tissue sarcomas. *CA Cancer J Clin*, 44(4):211-47, 1994.
36. Kalebic T, Tsokos M and Helman LJ. *In vivo* treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34^{cdc2}. *Cancer Res*, 54(21):5531-4, 1994.
37. Nolan EM, Helman LJ, Burton DW and Deftos LJ. Cloning of the human chromogranin-A promoter and identification of a sequence that possesses enhancer-like activity. *Endocrine*, 2:891-7, 1994.

38. Helman L. The role of insulin-like growth factors in rhabdomyosarcomas and osteosarcomas, pp 56-57. In: LeRoith D, moderator. Insulin-like growth factors and cancer. *Ann Intern Med*, 122:54-9, 1995.
39. Lee YL, Helman LJ, Hoffman T and Laborda J. dlk, pG2 and Pref-1 mRNAs encode similar proteins belonging to the EGF-like superfamily. Identification of polymorphic variants of this RNA. *Biochim Biophys Acta*, 1261:223-232, 1995.
40. Minniti CP, Luan D, O'Grady C, Rosenfeld RG, Oh Y and Helman LJ. Insulin-like growth factor II overexpression in myoblasts induces phenotypic changes typical of the malignant phenotype. *Cell Growth Differ*, 6:263-269, 1995.
41. Gaetano C, Manni I, Bossi G, Piaggio G, Soddu S, Farina A, Helman LJ and Sacchi A. Retinoic acid and cAMP differentially regulate human chromogranin A promoter activity during differentiation of neuroblastoma cells. *Eur J Cancer*, 31A:447-452, 1995.
42. Zhan S, Shapiro DN and Helman LJ. Loss of imprinting of IGF2 does not correlate with levels of IGF2 mRNA expression in Ewing's Sarcoma. *Oncogene*, 11: 2503-2507, 1995.
43. Zhan S, Shapiro DP, Zhan S, Zhang L, Hirschfeld S, Ellassal J and Helman LJ. Concordant loss of imprinting of the human insulin-like growth factor II gene promoters in cancer. *J Biol Chem*, 270:27983-27986, 1995.
44. Hernandez-Sanchez C, Blakesley V, Kalebic T, Helman L and LeRoith D. The role of the tyrosine kinase domain of the insulin-like growth factor-I receptor in intracellular signaling, cellular proliferation, and tumorigenesis. *J Biol Chem*, 270: 29176-29181, 1995.
45. LeRoith D, Werner H, Neuenschwander S, Kalebic T and Helman LJ. The role of insulin-like growth factor-I receptor in cancer. *Ann N Y Acad Sci*, 766: 402-405, 1995.
46. Blakesley VA, Kalebic T, Helman LJ, Stannard B, Faria TN, Roberts CT and LeRoith D. Tumorigenic and mitogenic capacities are reduced in transfected fibroblasts expressing mutant IGF-I receptors. *Endocrinol*, 137:410-4217, 1996.
47. Velez-Yanguas MC, Kalebic T, Maggi M, Kappel CC, Letterio J, Uskokovic M and Helman LJ. 1 α , 25-dihydroxy-16-ene-23-yne-26, 27-hexafluorocholecalciferol (Ro24-5531) modulation of insulin-like growth factor-binding protein-3 and induction of differentiation and growth arrest in a human osteosarcoma cell line. *J Clin Endocrinol Metab*, 81:93-99, 1996.
48. Zhang L, Kashanchi F, Zhan Q, Zhan S, Brady JN, Fornace AJ, Seth P and Helman LJ. Regulation of IGF-II P3 promoter by p53: a potential mechanism for tumorigenesis. *Cancer Res*, 56:1367-1373, 1996.
49. Toretsky JA and Helman LJ. Involvement of insulin-like growth factor II in human cancer. *J Endocrinol*, 149:367-372, 1996.

50. Kalebic T, Tsokos M and Helman LJ. Suppression of rhabdomyosarcoma growth by fumagillin analog TNP-470. *Int. J. Cancer*, 68:596-599, 1996.
51. Kalebic T, Uudde JG, Velez-Yanguas, M, Knutsen T and Helman LJ. Metastatic human rhabdomyosarcoma: molecular, cellular and cytogenetic analysis of a novel cellular model. *Invasion and Metastasis*, 16: 83-96, 1996.
52. Blakesley VA, Stannard B S, Kalebic T, Helman, L J and LeRoith D. Role of the IGF-1 receptor in mutagenesis and tumor promotion. *J. Endocrinol*, 152:339-344, 1997.
53. Schulte TW, Toretsky JA, Ress E, Helman L and Neckers LM. Expression of PAX3 in Ewing's sarcoma family of tumors. *Biochem Mol Med*, 60:121-126, 1997.
54. Toretsky J, Kalebic T, Blakesley V, LeRoith D and Helman L J. The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. *J. Biol. Chem*, 272:30822-30827, 1997.
55. Weintraub M, Kalebic T, Helman LJ and Bhatia KG. Disruption of the MyoD/p21 pathway in rhabdomyosarcoma. *Sarcoma*, 1, 135-141, 1997.
56. Zhang, L, Zhan Q, Zhan S, Kashanchi F, Fornace, Jr., A J, Seth P and Helman L J. p53 regulates human insulin-like growth factor II gene expression through active P4 promoter in rhabdomyosarcoma cells. *DNA and Cell Biol*, 17:125-131, 1998.
57. Kalebic T, Blakesley V, Slade C, Plasschaert S, LeRoith D and Helman, LJ. Expression of a kinase-deficient IGF-I-R suppresses tumorigenicity of rhabdomyosarcoma cells constitutively expressing a wild type IGF-I-R. *Int. J. Cancer*, 76, 223-227, 1998.
58. Zhan S, Zhan S, Zhang, L, Van M, Yeung C and Helman LJ. Biallelic expression of all four IGF-II promoters and its association with increased methylation of H19 gene in human brain. *Brain Research*, 792, 283-290, 1998.
59. Zhan S and Helman LJ. *Glimpsing* the cause of rhabdomyosarcoma. *Nature Medicine*, 4:559-560, 1998.
60. Zhang L, Zhan S, Navid F, Li Q, Choi YH, Kim M, Seth P, and Helman LJ. AP-2 may contribute to IGF-II overexpression in rhabdomyosarcoma. *Oncogene*, 17:1261-1270, 1998.
61. Wang W, Kumar P, Wang W, Epstein J, Helman L, Moore JV and Kumar S. Insulin-like growth factor II and PAX3-FKHR cooperate in the oncogenesis of rhabdomyosarcoma. *Cancer Res*, 58:4426-4433, 1998.
62. Zhang L, Kim M, Choi YH, Goemans B, Yeung C, Hu Z, Zhan S, Prem S and Helman LJ. Diminished G1 checkpoint after γ -irradiation and altered cell cycle regulation by IGFII overexpression. *J Biol Chem*, 274:13118-13126, 1999.

63. Merlino G and Helman LJ. Rhabdomyosarcoma – working out the pathways. *Oncogene*, 18:5340-5348, 1999.
64. Cope JU, Tsokos M, Helman, LJ, Gridley G and Tucker MA. Inguinal hernia in patients with Ewing sarcoma: A clue to etiology. *Med Ped Onc*, 34:195-199, 2000.
65. Liu XF, Helman LJ, Yeung C, Bera TK, Lee B and Pastan I. XAGE-1, a new gene that is frequently expressed in Ewing's sarcoma. *Cancer Res*, 60:4752-4755, 2000.
66. Navid F, Letterio JJ, Yeung CL, Pegtel M and Helman LJ. Autocrine transforming growth factor- β growth pathway in murine osteosarcoma cell lines associated with inability to affect phosphorylation of retinoblastoma protein. *Sarcoma*, 4:93-102, 2000.
67. Khanna C, Prehn J, Yeung C, Caylor J, Tsokos M and Helman L. An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential. *Clin Exper Metastasis*, 18:261-271, 2000.
68. Khanna C, Khan J, Nguyen P, Prehn J, Caylor J, Yeung C, Trepel J, Meltzer P and Helman L. Metastasis-associated differences in gene expression in a murine model of osteosarcoma. *Cancer Res*, 61:3750-3759, 2001.
69. Dagher R, Pham TA, Sorbara L, Kumar S, Long L, Bernstein D, Mackall, C, Raffeld M, Tsokos M and Helman L. Molecular confirmation of Ewing's sarcoma. *J Pediatr Hematol Oncol*, 23:221-224, 2001.
70. Dupont J, Fernandez AM, Glackin CA, Helman L and LeRoith D. Insulin-like growth factor I (IGF-1)-induced twist expression is involved in the anti-apoptotic effects of the IGF-1 receptor. *J Biol Chem*, 276:26699-26707, 2001.
71. Merino ME, Navid F, Christensen BL, Toretsky JA, Helman LJ, Cheung NK and Mackall CL. Immunomagnetic purging of Ewing's sarcoma from blood and bone marrow: quantitation by real-time polymerase chain reaction. *J Clin Oncol*, 19:3649-3659, 2001.
72. Dupont J, Khan J, Qu B-H, Meltzer P, Helman L and LeRoith D. Insulin and IGF-1 induce different patterns of gene expression in mouse fibroblast NIH-3T3 cells: identification by cDNA microarray analysis. *Endocrinology*, 142:4969-4975, 2001.
73. Worley BS, van den Broeke LT, Goletz TJ, Pendleton CD, Daschbach, EM, Thomas EK, Marincola FM, Helman LJ and Berzofsky JA. Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations. *Cancer Res*, 61:6868-6875, 2001.
74. Weil R, Zhuang Z, Pack S, Kumar S, Helman L, Fuller BG, Mackall CL and Oldfield EH. Intramedullary Ewing sarcoma of the spinal cord: consequences of molecular diagnostics. Case report. *J Neurosurg*, 95:270-275, 2001.

75. Toretzky JA, Steinberg SM, Thaker M, Counts D, Pironis B, Parente C, Eskenazi A, Helman L and Wexler LH. Insulin-like growth factor type 1 (IGF-I) and IGF binding protein-3 in patients with Ewing sarcoma family of tumors. *Cancer*, 192:2941-2947, 2002.
76. Dagher R, Long L, Read EJ, Leitman SF, Carter CS, Tsokos M, , Goletz TJ, Avila N, Berzofsky JA, Helman LJ and Mackall CL. Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study. *Med Pediatr Oncol*, 38:158-164, 2002.
77. Wan X and Helman LJ. Effect of insulin-like growth factor II on protecting myoblast cells against cisplatin-induced apoptosis via p70 S6 kinase pathway. *Neoplasia*, 4:400-408, 2002.
78. Khanna C, Prehn J, Hayden D, Cassaday RD, Caylor J, Jacob S, Bose SM, Hong S-H, Hewitt SM and Helman LJ. A randomized controlled trial of octreotide pamoate long-acting and carboplatin versus carboplatin alone in dogs with naturally occurring osteosarcoma: evaluation of insulin-like growth factor suppression and chemotherapy. *Clin Cancer Res*, 8:2406-2412, 2002.
79. Gobbi G, Sangiorgi L, Lenzi L, Casadei R, Canaider S, Strippoli P, Lucarelli E, Ghedini I, Donati D, Fabbri N, Warzecha J, Yeoung (sic Yeung) C, Helman LJ, Picci P and Carinci P. Seven BMPs and all their receptors are simultaneously expressed in osteosarcoma cells. *Int J Oncol*, 20:143-147, 2002.
80. Mansky PJ, Liewehr DJ, Steinberg SM, Chrousos GP, Avila NA, Long L, Bernstein D, Mackall CL, Hawkins DS and Helman LJ. Treatment of metastatic osteosarcoma with the somatostatin analog OncoLar®: Significant reduction of IGF-1 serum levels. *J Ped Hem Onc*, 24:440-446, 2002.
81. Houghton PJ, Adamson PC, Blaney S, Fine HA, Gorlick R, Haber M, Helman L, Hirschfeld S, Hollingshead MG, Israel MA, Lock RB, Maris JM, Merlino G, Patterson W, Reynolds CP, Shannon K, Yu A, Yu J, and Smith MA. Testing of new agents in childhood cancer preclinical models: meeting summary. *Clin Cancer Res*, 8:3646-3657, 2002.
82. Sharp R, Recio JA, Chamelli J, Otsuka T, Liu S, Yu Y, Liu W, Anver M, Navid F, Helman LJ, DePinho RA and Merlino G. Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis. *Nature Medicine*, 8:1276-1280, 2002. Corrigendum: *Nat Med*, 9:146, 2003.
83. Goorin AM, Schwartzentruber DJ, Devidas M, Gebhardt MC, Ayala AG, Harris MB Helman LJ, Grier HE and Link MP. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POB-8651. *J Clin Oncol*, 21:1574-1580. 2003.
84. Wan X and Helman LJ. Levels of PTEN protein modulate Akt phosphorylation on serine 473, but not on threonine 308, in IGF-II overexpressing rhabdomyosarcomas cells. *Oncogene*, 22:8205-8211, 2003.

85. Debelenko LV, Arthur DC, Pack SD, Helman LJ, Schrupp DS and Tsokos M. Identification of CARS-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor. *Lab Invest*, 83:1255-1265, 2003.
86. Zhang H, Merchant MS, Chua KS, Khanna C, Helman LJ, Telford B, Ward Y, Summers J, Toretsky J, Thomas EK, June CH and Mackall CL. Tumor expression of 4-1BB ligand sustains tumor lytic T cells. *Cancer Biol Ther*, 2:579-586, 2003.
87. Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A, Yeung C, Gorlick R, Hewitt SM and Helman LJ. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. *Nature Medicine*, 10:182-186, 2004.
88. Yu Y, Khan J, Khanna C, Helman L, Meltzer and Merlino G. Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. *Nature Medicine*, 10:175-181, 2004.
89. Toyoshima Y, Karas M, Yakar S, Dupont J, **Lee Helman (sic)** and LeRoith D. TDAG51 mediates the effects of insulin-like growth factor 1 (IGF-1) on cell survival. *J Biol Chem*, 24:25898-25904, 2004.
90. Nathan PC, Tsokos M, Long L, Bernstein D, Wexler LH, Mackall CL and Helman LJ. Adjuvant chemotherapy for the treatment of advanced pediatric nonrhabdomyosarcoma soft tissue sarcoma: The National Cancer Institute Experience. *Pediatr Blood Cancer*, 44:1-6, 2005.
91. Wan X, Mendoza A, Khanna C and Helman LJ. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. *Cancer Res*, 65:2406-2411, 2005.
92. Savage SA, Stewart BJ, Liao JS, Helman LJ and Chanock SJ. Telomere stability genes are not mutated in osteosarcoma cell lines. *Cancer Genetics and Cytogenetics*, 160:79-81, 2005.
93. Capponcelli S, Pedrini E, Cerone MA, Corti V, Fontanesi S, Alessio M, Bachi Soddu S, Ribatti D, Picci P, Helman LJ, Cantelli-Forti G and Sangiorgi L. Evaluation of the molecular mechanisms involved in the gain of function of a Li-Fraumeni TP53 mutation. *Hum Mutat*, 26:94-103, 2005
94. Man, T-K, Chintagumpala M, Visvanathan J, Shen J, Perlaky L, Hicks J, Johnson M, Davino N, Murray J, Helman L, Meyer W, Triche T, Wong K-K and Lau C. Expression profiles of osteosarcoma that can predict response to chemotherapy. *Cancer Res*, 65:8142-8150, 2005
95. Zhang H, Chua KS, Guimond M, Kapoor V, Brown MV, Fleisher TA, Long L, Bernstein D, Hill BJ, Douek DC, Berzofsky JA, Carter CS, Read EJ, Helman LJ and Mackall CL. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4(+)CD25(+) regulatory T cells. *Nat Med*, 11:1238-1243, 2005

96. van den Broeke LT, Pendleton CD, Mackall C, Helman LJ and Berzofsky, JA. Identification and epitope enhancement of a PAX-FKHR fusion protein breakpoint epitope in alveolar rhabdomyosarcoma cells created by a tumorigenic chromosomal translocation inducing CTL capable of lysing human tumors. *Cancer Res*, 66:1818-1823, 2006
97. Terabe M, Khanna C, Bose S, Melchionda F, Mendoza A, Mackall CL, Helman LJ and Berzofsky JA. CD1d-restricted natural killer T cells can down-regulate tumor immunosurveillance independent of Interleukin-4 receptor-signal transducer and activator of Transcription 6 or Transforming Growth Factor- β . *Cancer Res*, 66:3869-3875, 2006
98. Wan X, Shen N, Mendoza A, Khanna C and Helman LJ. CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1 α /VEGF signaling. *Neoplasia*, 8:394-401, 2006
99. Krishnan K, Bruce B, Hewitt S, Thomas D, Khanna C, and Helman LJ. Ezrin mediates growth and survival in Ewing's sarcoma through the AKT/mTOR, but not the MAPK, signaling pathway. *Clin Exp Metastasis*, 23:227-36, 2006
100. Merchant MS, Melchionda F, Sinha M, Khanna C, Helman L and Mackall CL. Immune reconstitution prevents metastatic recurrence of murine osteosarcoma. *Cancer Immunol Immunother*. 56:1037-46, 2007
101. Wan X, Harkavy B, Shen N, Grohar P, and Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. *Oncogene*, 26:1932-40, 2007
102. Petricoin EF 3rd, Espina V, Araujo RP, Midura B, Yeung C, Wan X, Eichler GS, Johann DJ Jr, Qualman S, Tsokos M, Krishnan K, Helman LJ and Liotta LA. Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. *Cancer Res*. 67:3431-40, 2007
103. Paz-Priel I, Long L, Helman LJ, Mackall CL and Wayne AS. Thromboembolic events in children and young adults with pediatric sarcoma. *J Clin Oncol*. 25:1519-24, 2007.
104. Tsai YC, Mendoza A, Mariano JM, Zhou M, Kostova Z, Chen B, Veenstra T, Hewitt SM, Helman LJ, Khanna C and Weissman AM. The ubiquitin ligase gp78 promotes sarcoma metastasis by targeting KAI1 for degradation. *Nat Med*. 13:1504-09, 2007, Letters.
105. Kummar S, Rubinstein L, Kinders R, Parchment RE, Gutierrez ME, Murgo AJ, Ji J, Mroczkowski B, Pickeral OK, Simpson M, Hollingshead M, Yang SX, Helman L, Wiltrout R, Collins J, Tomaszewski JE and Doroshow JH. Phase 0 clinical trials: conceptions and misconceptions. *Cancer J*. 14:133-137, 2008
106. Murgo AJ, Kummar S, Rubinstein L, Gutierrez M, Collins J, Kinders R, Parchment RE, Ji J, Steinberg SM, Yang SX, Hollingshead M, Chen A, Helman L, Wiltrout R, Tomaszewski JE and Doroshow JH. Designing Phase 0 cancer clinical trials. *Clin Cancer Res*, 14:3675-3682, 2008

107. Mackall C, Rhee E, Read E, Khuu H, Leitman S, Bernstein D, Tesso M, Long L, Grindler D, Merino M Kopp W, Tsokos M, Berzofsky J and Helman LJ. A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. *Clin Cancer Res*, 14:4850-4858, 2008.
108. Kim SY, Lee, CH, Midura BV, Yeung C, Mendoza A, Hong SH, Ren L, Wong D, Korz W, Merzouk A, Salari H, Zhang H, Hwang ST, Khanna C and Helman LJ. Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. *Clin Exp Metastasis, Research Paper*, 25:201-11, 2008.
109. Bielack SS, Marina N, Ferrari S, Helman LJ, Smeland S, Whelan JS and Reaman GH. Osteosarcoma: the same old drugs or more? *J Clin Oncol*. 26:3102-3, Author reply, 3104-5, 2008.
110. Wayne AS, Reaman GH and Helman LJ. Progress in the curative treatment of childhood hematologic malignancies. *J Natl Cancer Inst*. 100:1271-1273, 2008.
111. Mussai FJ, Cunningham LC, Rezvani G, Stratakis CA, Reynolds JC, Nesterova G, Henshaw RM, Levine JE, Helman LJ, Arthur DC and Kim SY. Hypocalcemia in a patient with osteosarcoma and 22q11.2 deletion syndrome. *J Pediatr Hematol Oncol*. 30:612-7, 2008.
112. Cao L, Yu Y, Darko I, Currier D, Mayeenuddin LH, Wan X, Khanna C and Helman LJ. Addiction to elevated insulin-like growth factor 1 receptor and initial modulation of AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. *Cancer Res*. 68:8039-48, 2008.
113. Hong SH, Briggs J, Newman R, Hoffman K, Mendoza A, Leroith D, Helman L, Yakar S and Khanna C. Murine osteosarcoma primary tumor growth and metastatic progression is maintained after marked suppression of serum insulin-like growth factor I. *Int J Cancer*. 124:2042-9, 2009.
114. Huang F, Greer A, Hurlburt W, Han X, Hafezi R, Wittenberg GM, Reeves K, Chen J, Robinson D, Li A, Lee FY, Gottardis MM, Clark E, Helman L, Attar RM, Dongre A and Carboni JM. The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. *Cancer Research*. 69:161-70, 2009.
115. Kim SY, Toretsky JA, Scher D and Helman LJ. The role of IGF-1R in pediatric malignancies. *Oncologist*. 14:83-91, 2009
116. Fitzhugh CD, Wise B, Baird K, Tsokos M, Helman L, Mackall C, Savage SA, Warren KE. Secondary supratentorial primitive neuroectodermal tumor following treatment of childhood osteosarcoma. *Pediatr Blood Cancer*. 53: 496-8, 2009.

117. Kummar S, Kinders R, Gutierrez ME, Rubinstein L, Parchment RE, Phillips LR, Ji J, Monks A, Low JA, Chen A, Murgu AJ, Collins J, Steinberg SM, Eliopoulos H, Giranda VL, Gordon G, Helman L, Wiltout R, Tomaszewski JE, Doroshow JH. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. *J. Clin. Oncol.* 27: 2705-11, 2009.
118. Wan X, Kim SY, Guenther LM, Mendoza A, Briggs J, Yeung C, Currier D, Zhang H, Mackall C, Li WJ, Tuan RS, Deyrup AT, Khanna C, Helman L. Beta4 integrin promotes osteosarcoma metastasis and interacts with ezrin. *Oncogene.* 2009.
119. Vi JG, Cheuk AT, Tsang PS, Chung JY, Song YK, Desai K, Yu Y, Chen QR, Shah K, Youngblood V, Fang J, Kim SY, Yeung C, Helman LJ, Mendoza A, Ngo V, Staudt LM, Wei JS, Khanna C, Catchpoole D, Qualman SJ, Hewitt SM, Merlino G, Chanock SJ and Khan J. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. *Journal of Clinical Investigation.* 119:3395-407, 2009
120. Fox E, Widemann BC, Hawkins DS, Jayaprakash N, Dagher R, Aikin AA, Bernstein D, Long L, Mackall C, Helman L, Steinberg SM and Balis FM. Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas. *Clin Cancer Res.* 15:7361-7, 2009. Epub 2009 Nov 17.

REVIEW ARTICLES AND BOOK CHAPTERS

1. Helman LJ, Thiele CJ, Linehan WM and Israel MA. A role for differentiation arrest in the development of neural crest tumors. In Lapis K, Liotta LA, and Rabson AS. (Eds): Biochemistry and Molecular Genetics of Cancer Metastases. Boston: Martinus Nijhoff Publishing 1986:73-82
2. Israel MA, Helman LJ and Miser JM. Patterns of proto-oncogene expression: A novel approach to the development of tumor markers. In DeVita VT, Hellman S, and Rosenberg SA. (Eds): Important Advances in Oncology 1987. Philadelphia: JB Lippincott Co 1987:87-104.
3. Thiele CJ, McKeon C, Helman LJ and Israel MA. Patterns of proto-oncogene expression: A tool to subtype histo-pathologically similar solid tumors. In Minna J and Kuelhl WM (Eds): Cellular and Molecular Biology of Tumors and Potential Clinical Applications. New York: Alan R Liss 1988:56:301-5.
4. Cooper MJ, Helman LJ and Israel MA. Molecular genetics and the diagnosis of peripheral nervous system tumors. In Cossman J (Ed): Molecular Genetics in Cancer Diagnosis. New York: Elsevier 1990:313-29.
5. Helman LJ, Cooper MJ, Cohen PS and Israel MA. Molecular biology of neuroblastoma and pheochromocytoma. In Lack EE and Oertel JE (Eds): Pathology of the Adrenal Glands. New York: Churchill Livingstone Inc 1991:311-21.
6. Thiele CJ and Helman LJ. New insights into the causes of cancer. In Pizzo PA and Horowitz ME (Eds) Pediatric Clinics of North America: Solid Tumors. Philadelphia: WB Saunders 1991:201-21.
7. Pizzo PA, Poplack DG, Magrath IT, Ungerleider RS, Balis FM, Helman LJ and Horowitz M. Cancers in children. In Wittes R (Ed): Manual of Oncologic Therapeutics. 1991/1992. Philadelphia: JB Lippincott Co 1991:287-303.
8. Helman LJ and Horowitz ME. Rhabdomyosarcoma. In Tonini GP, Sansone R, and Thiele CJ (Eds): Molecular Genetics of Pediatric Solid Tumors. Basic Concepts and Recent Advances. Chur, Switzerland: Harwood Academic Publishers 1992:337-58.
9. Thiele CJ and Helman LJ. Differentiating agents, growth factors, and novel molecular approaches to the treatment of pediatric cancer. In Pizzo PA and Poplack DG (Eds): Principles and Practice of Pediatric Oncology, 2nd ed. Philadelphia: JB Lippincott Co 1992:409-28.
10. Minniti CP and Helman LJ. IGF-II in the pathogenesis of rhabdomyosarcoma: a prototype of IGFs involvement in human tumorigenesis. In LeRoith D and Raizada MK (Eds.): Current Directions in Insulin-like Growth Factor Research. New York: Plenum Press 1994:327-43.
11. Wexler LH and Helman LJ. Rhabdomyosarcoma and the undifferentiated sarcomas. In: Pizzo PA and Poplack DG (Eds.): Principles and Practice of Pediatric Oncology, 3rd ed. Philadelphia: JB Lippincott Co., 1997:799-829.

12. Toretsky JA and Helman LJ. Cytogenetics and experimental models. In: *Current Opinion in Oncology*. 9:342-347:1997. Review.
13. Helman LJ and Wexler LH. Insulin-like growth factors and cytokines in pediatric cancer. Bondy C and LeRoith D (Eds.): Growth Factors and Cytokines in Health and Disease. Vol. 3B. pp. 331-354. JAI Press Inc. 1997.
14. Goletz TJ, Mackall CL, Berzofsky JA and Helman LJ. Molecular alterations in pediatric sarcomas: potential targets for immunotherapy. In: *Sarcoma*, 2:77-87, 1998. Review.
15. Dagher R and Helman L. Rhabdomyosarcoma: An Overview. In: *The Oncologist*. 4:34-44, 1999. Review.
16. Navid F and Helman LJ. Childhood cancers. Srivastava S, Henson DE and Gazdar A . (Eds.). Molecular Pathology of Early Cancer. Amsterdam, Netherlands: IOS Press, 1999: 123-134.
17. Mackall C, Berzofsky J and Helman LJ. Targeting tumor specific translocations in sarcomas in pediatric patients for immunotherapy. In: *Clinical Orthopaedics and Related Research*. 373:25-31, 2000. Review.
18. Berzofsky JA, Helman LJ and Carbone DP. Cancer Vaccines: Cancer Antigens: Oncogenes and Mutations. Rosenberg SA (ed.). Biologic Therapy of Cancer: Principles and Practice, 3rd ed. New Haven, CT: DHR Publishers, 2000: 526-541.
19. Wexler L and Helman L. Soft Tissue Sarcomas of Childhood. Cancer Medicine, 5th Ed. New York, NY: BC Decker, 2000, 2198-2203.
20. Mackall CL and Helman L. Targeting pediatric malignancies for T cell-mediated immune responses. In: *Current Oncology Reports*. 2:539-546:2000. Review.
21. Maher VE, Worley BS, Contois D, Smith MC, Kelley MJ, Stipanov M, Khleif SN, Goletz T, van den Broeke L, Mackall C, Helman LJ, Carbone DP and Berzofsky JA. Mutant Oncogene and Tumor Suppressor Gene Products and Fusion Proteins Created by Chromosomal Translocations as Targets for Cancer Vaccines. Kast MW (Ed). Peptide-Based Cancer Vaccines. Georgetown, TX: Landes Bioscience, and Austin, TX: Eurekah.com, 2000:17-39.
22. Rao VK and Helman L. Sarcomas and Malignancies of the Bone. Abraham J and Allegra C (Eds.) Bethesda Handbook of Clinical Oncology. Philadelphia: Lippincott Williams & Wilkins. 2001: 233-245.
23. Mackall CL and Helman LJ. High-dose chemotherapy for rhabdomyosarcoma: where do we go from here. Editorial Commentary, In: *J Pediatr Hematol Oncol*. 23:266-267, 2001. Review.
24. Helman, LJ. Book Review, Cancer Treatment, Haskell CM (ed.). Philadelphia, PA: WB Saunders, 2001. In: *Jnl Ped Hem-Onc*. 23:474. Review.

25. Helman L and Malkin D. Molecular Biology of Childhood Cancers. DeVita, Jr VT, Hellman S and Rosenberg, SA (Eds.). Cancer: Principles and Practice of Oncology, 6th Edition. Philadelphia, PA: Lippincott Williams & Wilkins, 2001:2161-2169.
26. Mackall CL, Goletz, TJ, Berzofsky, JA and Helman LJ. Toward New Approaches: Targeting Tumor Specific Molecular Alterations with Immune Based Therapy. Translocations in Solid Tumors. Georgetown, TX: Landes Bioscience, and Austin, TX: Eurekah.com. 2002: 180-195.
27. Wexler LH, Crist WM and Helman LJ. Rhabdomyosarcoma and the Undifferentiated Sarcomas. Pizzo PA and Poplack DG (Eds.). Principles and Practice of Pediatric Oncology, 4th Edition. Philadelphia, PA: Lippincott Williams & Wilkins, 2002:939-971.
28. Cohen KJ and Helman LJ. Pediatric Emergencies. Oncologic Emergencies. Eds. Johnston and Spence. Oxford, England: Oxford University Press, 2002:239-251.
29. Mackall CL, Meltzer PS and Helman LJ. Focus on sarcomas, In: Cancer Cell. 2:175-178, 2002. Review.
30. Navid F and Helman LJ. IGFs and sarcomas. Insulin-Like Grow Factors. Eds. Le Roith, Zumkeller and Baxter. Georgetown, TX: Eurekah.com, 2003.
31. Helman LJ and Meltzer P. Mechanisms of sarcoma development. In: Nat Rev Cancer, 3:685-694, 2003, Review.
32. Gorlick R, Anderson P, Andrulis I, Arndt C, Beardsley GP, Bernstein M, Bridge J, Cheung NK, Dome JS, Ebb D, Gardner T, Gebhardt M, Grier H, Hansen M, Healey J, Helman L, Hock J, Houghton J, Houghton P, Huvos A, Khanna C, Kieran M, Kleiner E, Ladanyi M, Lau C, Malkin D, Marina N, Meltzer P, Meyers P, Schofield D, Schwartz C, Smith MA, Toretzky J, Tsokos M, Wexler L, Wigginton J, Withrow S, Schoenfeldt M and Anderson B. Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Clin Cancer Res, 15:5442-5443, 2003. Review
33. Wayne AS and Helman LJ. Pediatric Malignancies. Pollock R. (Ed.). Union Internationale Contre le Cancer (UICC) Manual of Clinical Oncology, 8th Edition. UICC Education. John Wiley & Sons, Inc, 2004.
34. LeRoith D and Helman L. The new kid on the block(ade) of IGF-1 receptor. In: Cancer Cell. 5:201-202, 2004. Review. Erratum in: Cancer Cell. 5:403, 2004.
35. Mansky PJ and Helman L. Sarcomas and Malignancies of the Bone. Abraham J and Allegra C (Eds.) Bethesda Handbook of Clinical Oncology, 2nd Ed. Philadelphia: Lippincott Williams & Wilkins. 2005:265-279
36. Malawer MM, Helman LJ and O'Sullivan B. Sarcomas of the Bone. DeVita, Jr. VT, Hellman S and Rosenberg SA (Eds.). Cancer: Principles and Practice of Oncology, 7th Edition. Philadelphia, PA: Lippincott Williams & Wilkins, 2005:1638-1686.

37. Helman LJ and Malkin D. Molecular Biology of Childhood Cancers. DeVita, Jr. VT, Hellman S and Rosenberg SA (Eds.). Cancer: Principles and Practice of Oncology, 7th Edition. Philadelphia, PA: Lippincott Williams & Wilkins, 2005:1889-1937.
38. Krishnan K, Khanna C and Helman LJ. The biology of metastasis in pediatric sarcomas. *Cancer J*. 11:306-313, 2005. Review.
39. Khanna C and Helman L. Molecular approaches in Pediatric Oncology. *Ann Rev Med*. 57:83-97, 2006. Review
40. Wexler LH, Meyer WH and Helman LJ. Rhabdomyosarcoma and the Undifferentiated Sarcomas. Pizzo PA and Poplack DG (Eds.). Principles and Practice of Pediatric Oncology, 5th Edition. Philadelphia, PA: Lippincott Williams & Wilkins. 2006: 971-1001.
41. Krishnan K, Khanna C, and Helman LJ. The molecular biology of pulmonary metastases. *Thorac Surg Clin* 16:115-124, 2006. Review.
42. Kummur S, Kinders R, Rubinstein L, Parchment RE, Murgu AJ, Collins J, Pickeral O, Low J, Steinberg SM, Gutierrez M, Yang S, Helman L, Wiltout R, Tomaszewski JE and Doroshow JH. Compressing drug development timelines in oncology using phase '0' trials. *Nat Rev Cancer*. 7:131-9, 2007. Review.
43. Wan X and Helman LJ. The biology behind mTOR inhibition in sarcoma. *Oncologist*. 12:1007-18, 2007, Review.
44. Kinders R, Parchment RE, Ji J, Kummur S, Murgu AJ, Gutierrez M, Collins J, Rubinstein L, Pickeral O, Steinberg SM, Yang S, Hollingshead M, Chen A, Helman L, Wiltout R, Simpson M, Tomaszewski JE and Doroshow JH. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice. *Mol Interv*. 7:325-34, 2007, Review.
45. Malawer MM, Helman LJ and O'Sullivan B.. Sarcomas of Bone. DeVita, Jr. VT, Hellman S and Rosenberg SA (Eds.). Cancer: Principles and Practice of Oncology, 8th Edition, Volume 2. Philadelphia, PA: Lippincott Williams & Wilkins. 2008:1794-1833.
46. Helman LJ and Malkin D. Molecular Biology of Childhood Cancers. DeVita, Jr. VT, Hellman S and Rosenberg SA (Eds.). Cancer: Principles and Practice of Oncology, 8th Edition, Volume 2. Philadelphia, PA: Lippincott Williams & Wilkins. 2008:2033-2043.
47. Wan, X and LJ Helman. PI3K/Akt/mTOR Signaling Pathway: Implications for Human Cancer, Oncogene Proteins: New Research. Hauppauge, NY. Nova Science Publishers, Inc., in press.
48. Benjamin R, Pisters PWT, Helman LJ, Bramwell VHC, Rubin BP and O'Sullivan B. Sarcomas of Soft Tissue. Abeloff, et al. (Eds.). Clinical Oncology, 4th Edition. Philadelphia, PA: Elsevier Publishers. 2008:2009-2056
49. Kim SY, Tsokos M and Helman LJ. Dilemmas associated with congenital ewing sarcoma family tumors. *J Pediatr Hematol Oncol*, 30:4-7, 2008. Review

50. Kim SY, Wan X, Helman LJ. Targeting IGF-1R in the treatment of sarcomas: past, present and future. *Bulletin du cancer*. 96: E52-60, 2009. Review
51. Kim SY and Helman LJ. Strategies to Explore New Approaches in the Investigation and Treatment of Osteosarcoma, Pediatric and Adolescent Osteosarcoma. New York, NY: Springer Science+Business Media LLC. 2009:517-528
52. Wexler LH, Meyer WH and Helman LJ. Rhabdomyosarcoma and the Undifferentiated Sarcomas. Pizzo PA and Poplack DG (Eds.). Principles and Practice of Pediatric Oncology, 6th Edition. Philadelphia, PA: Lippincott Williams & Wilkins. In press.
53. Kim SY and Helman LJ. Strategies to Explore New Approaches in the Investigation and Treatment of Osteosarcoma, Pediatric and Adolescent Osteosarcoma, Cancer Treat Research, New York, NY: Springer Science+Business Media LLC. 2009:517-528